Reference
den Broeder N, et al. Three-year cost-effectiveness analysis of the DRESS study: protocolised tapering is key. Annals of the Rheumatic Diseases : 27 Aug 2018. Available from: URL: http://doi.org/10.1136/annrheumdis-2018-213547
Rights and permissions
About this article
Cite this article
Cost effectiveness of tapering TNF inhibitors maintained. PharmacoEcon Outcomes News 812, 12 (2018). https://doi.org/10.1007/s40274-018-5279-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5279-2